Hinge Health price target raised to $64 from $42 at BofA

BofA raised the firm’s price target on Hinge Health (HNGE) to $64 from $42 and keeps a Buy rating on the shares following what the firm calls “impressive 2Q results across the board.” Upside across both eligible lives and member yield points to momentum, says the analyst, who is increasing the firm’s estimates and sees margin upside speaking to scale and expanding unit economics as the company benefits from AI-driven efficiencies.